Taipei, Taiwan, February 10, 2025 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company headquartered in Taiwan, today announced its unaudited consolidated revenue for January 2025, reaching NT$2,171 million. This marks a significant 48% month-over-month (MoM) increase and 9% year-over-year (YoY) growth.
The export market saw robust performance, with sales surging 132% MoM and 13% YoY, driven primarily by strong Lenalidomide sales in the U.S. This growth offset the decline in gSuboxone and oncology product sales outside the U.S. Meanwhile, revenue from the Asia market increased 3% YoY, supported by the expansion of Lotus’s Thailand business since August 2024.
A key milestone for Lotus in January was the early completion of its acquisition of Alphachymotrypsine Choay® in Vietnam on January 7. Sales from this acquisition are expected to be recognized starting in Q1 2025. In 2023, Alphachymotrypsine Choay® generated US$22 million in annual sales across Vietnam and Cambodia, further strengthening Lotus’s footprint in Southeast Asia.
About Lotus
Founded in 1966, Lotus (1795: TT) is a global pharmaceutical company focused on delivering novel and generic medicines that are safer, better, and more accessible. With a best-in-class R&D and manufacturing platform in Asia, Lotus has partnerships in key markets including the U.S., Europe, Japan, China, and Brazil. The company manages over 100 strategic projects in development and registration across Asia and the U.S., with a portfolio of more than 250 commercial products. Lotus invests in a diversified pipeline of high-barrier oncology treatments, complex generics, 505(b)2 products, and new chemical entities (NCEs), through internal R&D and licensing partnerships. Additionally, it bolsters its portfolio with biosimilars, supported by strategic alliances. Lotus's facilities are certified by top regulatory bodies, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.